You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Measuring Activities of Daily Living in Stroke Patients with Motion Artificial Intelligence

    SBC: NEWVENTUREIQ LLC            Topic: Na

    The goal this project is to create a motion artificial intelligence (AI) analysis software to monitor activities of daily living (ADL) for stroke survivors with disabilities. The project utilizes wearable smart devices and a supervised machine learning (ML) algorithm to monitor activities that are meaningful and useful for clinicians and healthcare providers. Objectives are: (1) create a working M ...

    SBIR Phase I 2019 Department of Health and Human ServicesAdministration for Community Living
  2. Object Oriented Data Analysis for Untargeted Metabolomics

    SBC: WILLIAM D SHANNON CONSULTING LLC            Topic: 400

    PROJECT SUMMARY ABSTRACT In this Phase I SBIR applicationwe propose to develop and optimize functional Object Oriented Data AnalysisfOODAmethods and create a cloud based SaaS platform to analyze untargeted metabolomics dataUntargeted metabolomics quantifies the amount of known and unknown metabolites in samples with the purpose of finding known and unknown metabolites that correlate with subgroups ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Developing a Nutraceutical Product against Ototoxicity

    SBC: GATEWAY BIOTECHNOLOGY, INC.            Topic: NIDCD

    PROJECT SUMMARYDespite recent advances in cancer therapiesplatinum based drugs are still widely used for the treatment of solid tumorsA primary example is cisplatinwhich is frequently used to treat lungbladdertesticularand cervical cancersHoweverlimitations of this therapy include the development of drug resistance in cancer cells as well as severe side effectssuch as nephrotoxicity and neurotoxic ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Rapid high-resolution typing of Human Leukocyte Antigen genes by nanopore sequencing for transplantation

    SBC: NEWVENTUREIQ LLC            Topic: NIAID

    ABSTRACT Human leukocyte antigenHLAtyping is an essential laboratory test to evaluate the donor recipient compatibility before life saving transplantationsInaloneHLA typing of donors and recipients guided overorgan and stem cell transplantations in the United StatesExisting high resolution HLA typing methods require a turnaround time of days to weeksThere has been an unmet clinical need for a rapi ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Biologically Targeted Vaccine for Chikungunya

    SBC: PRECISION VIROLOGICS INC            Topic: NIAID

    PROJECT SUMMARY ABSTRACT Chikungunya virusCHIKVis a mosquito transmitted alphavirus that causes explosive epidemics of a severe febrile illness characterized by debilitating polyarthralgia in humansCHIKV caused an estimatedmillion new cases in India alone inand has the potential to spread globally because of the distribution and abundance of its mosquito vectorsAedes aegypti and Aedes albopictusDu ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Magnetomotive Embolization for Hepatocellular Carcinoma

    SBC: UNANDUP, LLC            Topic: 102

    Cancer is thend leading cause of death in the United StatesUSand accounts forof everydeathsMore thanAmericans will die of cancer inwith annual US cancer care expenditures reaching $B byand more thanM cancer related deaths occur annuallyWhile chemotherapy is effectiveseveral cancer subtypesincluding liver cancerare associated with a very lowyear survival rate of less thanIn additiononly a small pro ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Humanization, Production, and PK/PD Characterization of anti-TIP1 antibody against Non-Small Cell Lung Cancer

    SBC: Medical Guidance Systems LLC            Topic: 102

    The proposed developmental activity will result in a humanized monoclonal antibody, Tiptuhumab, which acts as a radiomodulator/immunotherapeutic. This antibody targets the cancer neoantigen, Tax Interacting Protein-1 (TIP-1), and is cytotoxic to non-small-cell lung cancer cells, NSCLC. For patients with NSCLC, the 5-year overall survival rate is 14.9% with a median survival time of 4 months. The c ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a novel immunomodulatory pyridone for the treatment of acute heart damage

    SBC: I-Cordis, LLC            Topic: NHLBI

    Project summary abstract In the USpeople per year develop heart failure from acute heart damagemostly from heart attacksApproximatelyof them die withinyears of the heart failure diagnosisCurrentlythere are no therapies to prevent the development of heart failure after acute heart damageA growing body of evidence points at Pirfenidonea pyridone currently approved for the treatment of a rare disease ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a bioconjugate vaccine against Group B Streptococcus

    SBC: VaxNewMO            Topic: NIAID

    PROJECT SUMMARY Streptococcus agalactiae, commonly referred to as Group B Streptococcus (GBS), is a leading cause of neonatal meningitis and sepsis worldwide as well as an agent of invasive disease in both pregnant and non-pregnant adults. GBS neonatal disease manifests as early onset, defined as disease within the first six days after birth, or late onset, defined as disease occurring after the f ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Use of mimotope vaccine technology to develop vaccines against bacterial pathogens

    SBC: ZenVax LLC            Topic: NIAID

    ABSTRACT This Small Business Technology TransferSTTRPhase I proposal is in response toNIH NIAID Research Topics in Division of Microbiology and Infectious Diseases and Bacteriology and Mycology BranchVaccine for prevention of human Q feverQ fever is a worldwide zoonotic disease that is caused by the obligate intracellular Gram negative bacteriumCoxiella burnetiiThe highly infectious nature of Cbur ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government